In Re Zyprexa Products Liability Litigation

433 F. Supp. 2d 268, 2006 WL 1549728
District Court, E.D. New York·Decided June 8, 2006·No. 04-MD-01596 (JBW)·Published·Cited by 13 cases

Opinion

MEMORANDUM AND ORDER REGARDING CONTROL BY COURT OF ATTORNEYS AND CLIENTS IN AGGREGATED INDIVIDUAL CASES

WEINSTEIN, Senior District Judge.

I. Introduction and Summary

This mass tort action on behalf of over 8,000 private individuals against the pharmaceutical manufacturer Eli Lilly and Co. was transferred to this court by the Judicial Panel on Multidistrict Litigation on April 14, 2004. See 28 U.S.C. § 1407. A Final Settlement of the bulk of the cases was approved by the court and parties on November 22, 2005. Over 99% of the “settling plaintiffs” filed consents and releases. A large sum has been deposited in escrow to pay plaintiffs’ individual claims when approved by the four Special Settlement Masters appointed by the court. The amounts of the payments will be determined by the Special Settlement Masters *270 according to matrixes approved by the court.

The proceeding now requires the court to exercise its equitable and inherent powers to ensure that all settling litigants are treated fairly.

In large part because of inadequate documentary support, only about half of the claims have been approved for payment by the Special Settlement Masters. No money can be paid to any claimant under the terms of the settlement until some 86% of the claims have been so approved.

For the reasons indicated below, the court now orders that by July 17, 2006 all settling plaintiffs who have not yet done so must have filed documents necessary to support their claims, conforming to the guidelines agreed upon in the Final Settlement Protocol, so that all pending settled cases can be approved for payment by the Special Settlement Masters by August 1, 2006. Any plaintiff who fails to comply— either by submitting an inadequately supported claim, or by failing to submit necessary documents — will be deemed to have abandoned the claim; the complaint will be dismissed with prejudice and the case reinstated only upon submission of affidavits showing good cause for the delay and a substantial basis for the renewed claim.

II. Facts

Members of the Plaintiffs’ Steering Committee (“PSC”) and other plaintiffs’ attorneys reached an agreement with Eh Lilly and Co. (“Lilly”) in principle to settle a significant number of Zyprexa personal injury cases pursuant to a June 8, 2005 Memorandum of Understanding. See Order of June 30, 2005. Special Settlement Masters were appointed by the court to assist the parties in effectuating the settlement. See id. A Final Settlement Protocol was approved by the court after consulting with the PSC, other parties, and the Special Settlement Masters. See Order of November 22, 2005. A large sum has been deposited in an escrow fund, subject to court order, where it collects interest. See Order of August 15, 2005; Tr. of Status Conf., June 1, 2006. No money has been paid to any claimant.

It has been almost one year since the original Memorandum of Understanding was issued, and six months since the Final Settlement Proposal was approved. Some 99.6% of eligible plaintiffs — representing 8,362 individuals — have tendered releases to Lilly. See Letter of Christopher A. Seeger dated May 17, 2006. The Special Settlement Masters report that 4,087 claims have been approved by them for payment. Tr. of Status Conf., June 1, 2006.

Pursuant to the settlement agreement, no payment can be made to any of the more than 8,000 individuals who are participating in the settlement until at least 7,193 claims have been properly filed and approved by the Settlement Masters; 6,474 of these claims must be diabetes-related. According to the Special Masters, only 3,737 diabetes-related claims have been approved to date. That means an additional 3,106 claims — 2,737 of them diabetes-related — must be approved before the Special Settlement Masters can authorize payments to anyone or the court can release any money from the escrow fund. Id.

The delay appears to be due in large part to the failure of some participating attorneys to provide the Settlement Masters promptly with appropriate documents supporting their claims.

At a Status Conference held June 1, 2006, Special Settlement Master Kenneth Feinberg reported that approximately one-third of potential claimants had delivered supporting documents that did not con *271 form with the instructions for claim submission, while many others have not even filed claim forms. Id.

Those attorneys who have failed to meet them obligation to support their clients’ claims promptly and properly cannot be allowed to imperil their own and every other attorney’s clients by needless delay, placing unjust and unnecessary obstacles in the way of prompt payment of valid claims. The public interest and that of the parties, as a matter of law and equity, require prompt payment to those who have properly filed and supported valid claims.

III. Law

A. Quasi-Class Action

While the settlement in the instant action is in the nature of a private agreement between individual plaintiffs and the defendant, it has many of the characteristics of a class action; it may be characterized properly as a quasi-class action subject to the general equitable power of the court. See Fed.R.Civ.P. 23(g)(l)(C)(iii); Fed. R.Civ.P. 23(h); Fed.R.Civ.P. 1 (“just ... determination of every action”); cf. Fed. R.Civ.P. 23(e)(1)—(2) (dealing with approval of terms of settlement). See also In re Zyprexa Prods. Liab. Litig., 424 F.Supp.2d 488, 490 (E.D.N.Y.2006) (quasi-class action status of aggregated claims for fee purposes). Cf. United States v. Miami, 614 F.2d 1322, 1330 (5th Cir.1980) (discussing the “special situations in which the trial court is required by statute or rule to approve a settlement”). The large number of plaintiffs subject to the same settlement matrix approved by the court, the utilization of special masters appointed by the court to control discovery and to assist in reaching and administering a settlement, the court’s order approving and controlling a huge escrow fund, other interventions by the court in controlling discovery for all claimants, the employment of a multidistrict reference, and cooperation among many federal and state courts, reflect a degree of court control that supports the imposition of fiduciary standards to ensure fair treatment to all parties and counsel regarding issues such as settlement procedures. See In re Zyprexa Prods. Liab. Litig., 424 F.Supp.2d at 491. In addition, the viability of an effective pharmaceutical industry and public health considerations necessitate efficient and fair control by the courts of cases of this kind.

Free access — add to your briefcase to read the full text and ask questions with AI

In Re Zyprexa Products Liability Litigation, 433 F. Supp. 2d 268, 2006 WL 1549728 (E.D.N.Y. 2006).

433 F. Supp. 2d 268 (In Re Zyprexa Products Liability Litigation) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Andrews v. Blick Art Materials, LLC
286 F. Supp. 3d 365 (E.D. New York, 2017)
Hood ex rel. Mississippi v. Eli Lilly & Co.
671 F. Supp. 2d 397 (E.D. New York, 2009)
Earl v. Eli Lilly & Co.
688 F. Supp. 2d 130 (E.D. New York, 2009)
In Re Zyprexa Products Liability Litig.
688 F. Supp. 2d 130 (E.D. New York, 2009)
In Re Zyprexa Products Liability Litigation
649 F. Supp. 2d 18 (E.D. New York, 2009)
Head v. Eli Lilly & Co.
649 F. Supp. 2d 18 (E.D. New York, 2009)
Souther v. Eli Lilly & Co.
489 F. Supp. 2d 230 (E.D. New York, 2007)